NICE
NICE gives initial ‘no’ to NHS England for kidney cancer drug
February 18, 2020Manufacturing and Production NHS England, NICE, clinical trials, inlyta, keytruda
The National Institute for Health and Care Excellence (NICE) has not recommended Keytruda (pembrolizumab) and Inlyta (axitinib) for the treatment …
Experts call on NICE to recommended a ban on OTC codeine sales
February 17, 2020Research and Development, Sales and Marketing Codein, NICE, opioid crisis, opioids, prescription drugs
Experts have called for a ban on the sale of over the counter codeine as NICE is set to publish …
NICE does not recommend cancer drug combination to the NHS
February 13, 2020Business Services Cancer, Kidney cancer, NHS, NICE, keytruda, kidney disease
NICE has published draft guidance that does not recommend a new drug combination to combat untreated advanced renal cell carcinoma …
New report finds that health inequality in the UK greater than previously thought
February 12, 2020Research and Development NHS, NICE, type 2 diabetes
Men are living seven years in poor health while women are living nearly ten years, according to a new report. …
NICE plans to use broader range of data in guidance
February 5, 2020Research and Development NHS, NHS NICE, NICE
The British National Institute for Care Excellence has said it plans to use a broader range of data and analytics …
Top Ten most popular articles on Pharmafile.com this week
January 31, 2020Medical Communications Janseen, Ketamine, NHS, NICE, Nasal sprays, Nasl, Top 10 of the week, top 10
This week nasal sprays based on illegal recreational drugs feature prominently, as the FDA has moved to approve Lannett Company’s …
NICE rejects Janssen’s esketamine nasal spray Spravato for treatment-resistant depression
January 28, 2020Manufacturing and Production, Sales and Marketing Janssen, NHS, NICE, Spravato, depression
Janssen’s Spravato (esketamine) nasal spray, derived from the party drug ketamine, has been turned down by NICE for NHS use …
NICE refuses Novo Nordisk’s obesity therapy Saxenda for NHS use
January 27, 2020Sales and Marketing NHS, NICE, Novo Nordisk, UK, obesity, saxenda
NICE, the drug watchdog for England and Wales, has revealed that it has chosen not to recommend Novo Nordisk’s Saxenda …
NICE declines to recommend Astellas’ Xospata in rlapsed/refractory FLT3+ acute myeloid leukaemia
January 23, 2020Sales and Marketing Astellas, NHS, NICE, UK, Xospata, acute myeloid leukaemia
The latest in a series of rejections over the past week, NICE has revealed that it has knocked back the …
No NICE recommendation for AstraZeneca’s Tagrisso in EGFR+ lung cancer
January 22, 2020Research and Development, Sales and Marketing AstraZeneca, NICE, Tagrisso, pharma
AstraZeneca’s Tagrisso (osimertinib) has been knocked back for routine use on the NHS in England and Wales by the drug …
Janssen’s ulcerative colitis medicine not recommended by NICE for use in adults
January 21, 2020Manufacturing and Production IBS, Irrated Bowels, NHS, NICE, bowel, ulcerative colitis
NICE has published draft guidance which does not recommend Stelara (ustekinumab) for treating moderately to severely active ulcerative colitis in …
Novartis’ Mayzent granted license by the European Medicines Agency
January 21, 2020Manufacturing and Production CNS, European Medicines Agency, NHS, NICE, Novartis
The European Medicines Agency (EMA) has granted a licence for the use of Mayzent (siponimod) in the treatment of certain …
NICE turns down Bayer’s tumour-agnostic therapy Vitrakvi over evidence concerns
January 20, 2020Sales and Marketing Bayer, Cancer, NICE, Vitravki
UK drug watchdog NICE has turned down Bayer’s Vitrakvi (larotrectinib) as a tumour-agnostic treatment solution on the NHS after it …
Lynparza tablets approved for NHS use in platinum-sensitive, BRCA-mutated ovarian, fallopian tube or peritoneal cancer
January 16, 2020Sales and Marketing AstraZeneca, MSD, NHS, NICE, UK, lynparza
It has been announced that tablet form of Lynparza (olaparib), the PARP inhibitor developed by AstraZeneca and MSD, has secured …
NICE shoots down Keytruda in head and neck cancer over data concerns
January 16, 2020Sales and Marketing Cancer, NHS, NICE, UK, keytruda, pharma
It has been revealed that NICE has chosen to reject MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) for routine use on the …
Latest content
FibroFind appoints Lee Borthwick as CEO
